Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Other Events
Item 8.01
|
Other Events.
|
Report on Form 8-K (the Form 8-K) to correct an inadvertent error
in the number of securities remaining available for future
issuance under the Companys equity compensation plans disclosed
in the Companys Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 1, 2017 (the Form
10-K), as detailed below.
Form 10-K is corrected as follows:
regarding compensation plans under which our equity securities
are authorized for issuance>or sale:
|
Plan
|
Number of Securities to be Issued Upon Exercise of
Outstanding Options, Warrants and Rights |
Weighted-Average Exercise Price of Outstanding Options,
Warrants and Rights ($) |
Number of Securities Remaining Available for Future
Issuance or Sale Under Equity Compensation Plans |
|||
|
2002 Equity Incentive Plan (approved by stockholders)
|
2,233,393
|
$22.67
|
542,608
|
|||
|
1999 Equity Incentive Plan (approved by stockholders)
|
$11.85
|
296,921 (1)
|
||||
|
2001 Non-Qualified Employee Stock Purchase Plan (not
approved by stockholders) |
51,638
|
|||||
|
Total
|
2,234,331
|
N/A
|
891,167
|
awards under our 1999 Equity Incentive Plan.
Compensation in the Form 10-K is amended and restated as follows:
for issuance under its 2002 Plan. Although there were also
296,921 shares available for issuance under its 1999 Plan, the
Company determined that it will cease granting equity awards
under this plan. Additionally, the Company had 51,638 shares
available for sale under its 2001 Non-Qualified Employee Stock
Purchase Plan (ESPP).
supplement or otherwise affect the Form 10-K.
About Impax Laboratories, Inc. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches. Impax Laboratories, Inc. (NASDAQ:IPXL) Recent Trading Information
Impax Laboratories, Inc. (NASDAQ:IPXL) closed its last trading session up +0.45 at 12.60 with 1,186,976 shares trading hands.
